News

Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...
Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
Lilly’s Zepbound Trims More Belly Fat Than Novo’s Wegovy
Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...
Zepbound trims more belly fat than Wegovy, study shows
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
BioSpace4d
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
Zepbound outperforms Wegovy in head-to-head weight loss trial
Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.
Is Eli Lilly and Company (LLY) the Best Major Stock to Buy According to Billionaires?
We recently published a list of 12 Best Major Stocks to Buy According to Billionaires. In this article, we are going to take ...